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Aims We sought to examine the diagnostic and prognostic utility of sensitive cardiac troponin (cTn) assays in patients with
pre-existing coronary artery disease (CAD).
Methods
and results
We conducted a multicentre study to examine the diagnostic accuracy of one high-sensitive and two sensitive cTn
assays in 1098 consecutive patients presenting with symptoms suggestive of acute myocardial infarction (AMI), of
whom 401 (37%) had pre-existing CAD. Measurements of Roche high-sensitive cTnT (hs-cTnT), Siemens cTnI-
Ultra, Abbott-Architect cTnI and the standard assay (Roche cTnT) were performed in a blinded fashion. The final
diagnosis was adjudicated by two independent cardiologists. Acute myocardial infarction was the final diagnosis in
19% of CAD patients. Among patients with diagnoses other than AMI, baseline cTn levels were elevated above
the 99th percentile with Roche hs-cTnT in 40%, with Siemens TnI-Ultra in 15%, and Abbott-Architect cTnI in
13% of them. In patients with pre-existing CAD, the diagnostic accuracy at presentation, quantified by the area
under the receiver operator characteristic curve (AUC), was significantly greater for the sensitive cTn assays com-
pared with the standard assay (AUC for Roche hs-cTnT, 0.92; Siemens cTnI-Ultra, 0.94; and Abbott-Architect cTnI,
0.93 vs. AUC for the standard assay, 0.87; P, 0.01 for all comparisons). Elevated levels of cTn measured with the
sensitive assays predicted mortality irrespective of pre-existing CAD, age, sex, and cardiovascular risk factors.
Conclusion Sensitive cTn assays have high-diagnostic accuracy also in CAD patients. Mild elevations are common in non-AMI
patients and test-specific optimal cut-off levels tend to be higher in CAD patients than in patients without history
of CAD. Sensitive cTn assays also retain prognostic value. (ClinicalTrials.gov number, NCT00470587).
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Introduction
Acute myocardial infarction (AMI) is a major cause of death and
disability. Its rapid and accurate diagnosis is critical for effective
evidence-based medical management and treatment,1,2 but still
an unmet clinical need. Delayed ‘rule-in’ increases morbidity and
mortality, particularly in patients with pre-existing coronary
artery disease (CAD).3,4 Delayed ‘rule-out’ prolongs the time
spent in the emergency department (ED), increasing patients’
anxiety, and causes enormous costs for the health-care system.5
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More sensitive cardiac troponin (cTn) assays with a limit of
detection (LoD) below the 99th percentile of a reference popu-
lation and improved precision have recently become available in
clinical practice.6 –8 These assays improved the early diagnosis of
AMI in unselected patients with acute chest pain.9,10 However,
their diagnostic accuracy in patients with pre-existing CAD is
uncertain, as recently elevated cTn levels were found in .10%
of patients with stable CAD.11,12
Also for several other reasons, patients with pre-existing CAD
merit particular attention. First, they are at increased risk for
both AMI as well as anxiety related to non-cardiac causes of
chest pain. Secondly, interpretation of a 12-lead electrocardiogra-
phy (ECG) is challenging in these patients: pre-existing ST-segment
and T-wave alterations are frequent, and new ST-segment
elevation is less common in patients with pre-existing CAD.13
Thirdly, the utility of CT angiography is considerably reduced in
such patients.14,15 Fourthly, the impact of myocardial loss is par-
ticularly devastating when the ventricles have already suffered pre-
vious assaults, and delayed diagnosis of AMI yields especially severe
consequences.3,4 We therefore examined the diagnostic perform-
ance of more sensitive cTn assays for the early diagnosis of AMI in
patients with pre-existing CAD, presenting with acute chest pain
to the ED.
Methods
Study design and population
The Advantageous Predictors of Acute Coronary Syndrome Evaluation
(APACE) Study is an ongoing prospective multicentre study designed,
coordinated by the University Hospital Basel. From April 2006 to June
2009, a total of 1247 consecutive patients presenting to the ED with
chest pain suggestive of AMI with onset or peak within the last 12 h
were recruited. Patients with end-stage renal failure requiring dialysis
were excluded. Pre-existing CAD was defined as history of previous
AMI, previous coronary revascularization for obstructive CAD, or
known coronary artery stenosis exceeding 50%. For analysis, patients
were included if baseline values of all four cTn assays were available.
The study was carried out according to the principles of the
Declaration of Helsinki and approved by the local ethics committees.
Written informed consent was obtained from all patients. The
authors designed the study, gathered and analysed the data, vouch
for the data and analysis, wrote the paper, and made the decision to
submit it for publication. The assays were donated by the manufac-
turers, who had no role in the design of the study, data analysis, manu-
script, or decision to submit for publication.
Routine clinical assessment
All patients underwent an initial clinical assessment that included
history-taking, a physical examination, 12-lead ECG, continuous ECG
monitoring, pulse oximetry, standard blood tests, and chest radiogra-
phy. Cardiac troponin I or cTnT, CK-MB, and myoglobin were
measured at presentation and 6–9 h after, or as long as clinically indi-
cated. The precise timing of clinical post-baseline measurements and
the treatment of patients were left to the discretion of the attending
physician.
Adjudicated final diagnosis
To determine the final diagnosis for each patient, two independent
cardiologists reviewed all available medical records from the time of
the patient’s arrival in the ED to the end of the 90-day follow-up
period. When there was disagreement about the diagnosis, cases
were reviewed and adjudicated in conjunction with a third
cardiologist.
An AMI, ST-elevation or Non-ST-elevation myocardial infarction,
was defined in accordance with current guidelines.16 In brief, an AMI
was diagnosed when there was evidence of myocardial necrosis in
association with clinical signs of myocardial ischaemia and/or ECG find-
ings suggestive of myocardial ischaemia. Necrosis was diagnosed by a
30% rising and/or falling pattern of the local cTn level, with at least
one value above the 99th percentile, at a level of imprecision of
,10% (for detailed information see Supplementary material online,
Appendix).6,17 The following cTn assays were used for the adjudication
of the final diagnosis at participating hospitals: Abbott-Axsym cTnI
ADV, Beckmann Coulter Accu cTnI, and Roche cTnT. All three are
well-validated current cTn assays with comparable performance in
the diagnosis of AMI.6,17 Unstable angina (UA) was diagnosed when
a patient had normal cTn levels and typical angina at rest, a deterio-
ration of a previously stable angina, in cases of positive cardiac exercise
testing or cardiac catheterization showing coronary arteries with ste-
nosis of 70% or more of the vessel diameter, or when the diagnosis
was uncertain but follow-up information showed that the patient
had an AMI or a sudden cardiac death within 60 days after presen-
tation. Further predefined diagnostic categories included cardiac but
not coronary symptoms (e.g. tachyarrhythmias), non-cardiac causes,
and symptoms of unknown origin. If AMI was ruled out in the ED
but no sufficient diagnostic procedures were performed to establish
a conclusive diagnosis, symptoms were classified as being of
unknown origin.
Cardiac troponin analysis
Blood samples for determination of cTn levels with four cTn assays
one high-sensitive cTnT (hs-cTnT) assay: Roche high-sensitive-cTnT;18
two sensitive cTnI assays: Siemens cTnI-Ultra,7,8 Abbott-Architect
cTnI;18 and one standard cTnT assay: Roche cTnT,18,19 were collected
into tubes containing potassium EDTA or serum within the first hour
of the patient’s presentation to the ED. Additional samples were col-
lected at 1, 2, 3, and 6 h. Serial sampling was discontinued when the
diagnosis of AMI was certain and treatment required transferring the
patient to the catheter laboratory or coronary care unit. After cen-
trifugation, samples were frozen at 2808C until they were assayed
in a blinded fashion in two batches in a dedicated core laboratory. In
contrast to the standard assay, the more sensitive cTn assays have a
LoD below the 99th percentile of a normal reference population.7,8,18
All Roche assays were performed with the use of the Elecsys 2010
system (Roche Diagnostics): cTnT (fourth generation) with a LoD of
0.01 ng/mL, a 99th percentile cut-off point of ,0.01 ng/mL, and a coef-
ficient of variation of ,10% at 0.035 ng/mL; and high-sensitive-cTnT
with a LoD of 0.003 ng/mL (3 ng/L), a 99th percentile cut-off point
of 0.014 ng/mL (14 ng/L), and a coefficient of variation of ,10% at
0.013 ng/mL (13 ng/L).20 The Siemens cTnI-Ultra assay was performed
with the use of the ADVIA Centaur immunoassay system (Siemens),
with a LoD of 0.006 ng/mL (6 ng/L), a 99th percentile cut-off point
of 0.04 ng/mL (40 ng/L), and a coefficient of variation of ,10% at
0.03 ng/mL (30 ng/L), as specified by the manufacturer.7 –9 The
Abbott-Architect cTnI assay was performed with the use of the Archi-
tect system (Abbott Diagnostics), with a LoD of 0.01 ng/mL (10 ng/L),
a 99th percentile cut-off point of 0.028 ng/mL (28 ng/L), and a coeffi-
cient of variation of ,10% at 0.032 ng/mL (32 ng/L), as specified by
the manufacturer.
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Statistical analysis
Continuous variables are presented as means (+SD) or medians (with
the inter-quartile range), and categorical variables as numbers and per-
centages. Continuous variables were compared with the use of the
Mann–Whitney test and categorical variables with the use of the
Pearson-x2-square test. Receiver operating characteristic (ROC)
curves were constructed to assess the sensitivity and specificity of
cTn measurements obtained at specific times with the four assays
and to compare their ability to diagnose AMI. Logistic regression
was used to combine cTn levels at presentation with early changes
in cTn levels. The comparison of areas under the ROC curves
(AUC) was performed as recommended by DeLong et al.21 The
optimal cut-off values were determined by the minimal distance of
the ROC-curve to the point (0;1) of the graph. We used the relevant
cross table at this cut-off point to calculate sensitivity and its 95% con-
fidence interval (95% CI), and determined the troponin values around
this cut-off, that corresponded to the 95% CI.22 Sensitivities and spe-
cificities were compared with a Mc Nemar x2 test in the case of paired
binary outcomes.23 In the case of independent binary outcomes, we
used the x2 test to compare sensitivity, specificity, and positive, and
negative predictive values. For the analysis of the prognostic value of
the sensitive cTn assays, we did Kaplan–Meier analysis and presented
cumulative survival rates at 1 year, subgrouping for pre-existing CAD,
diagnosed AMI and elevated sensitive cTn levels above the 99th per-
centile. We estimated 95% CIs estimated by the standard error. Fur-
thermore, we performed a separate Cox regression analysis for each
assay including the cTn elevation above the 99th percentile, pre-
existing CAD, age, sex, and cardiovascular risk factors that represented
independent predictors for death (arterial hypertension and diabetes)
and for AMI during follow-up (arterial hypertension and hypercholes-
terolaemia) in univariate regression models. All hypothesis testing was
two-tailed, and P-values of ,0.05 were considered to indicate statisti-
cal significance. All statistical analyses were performed with the use of
SPSS for Windows, version 15.0 (SPSS), MedCalc software, version
10.3.0 (MedCalc), and the R statistical package (online at http://www.
R-project.org).
Results
Characteristics of the patients
Of the 1247 consecutively enrolled patients, measurement of all
four cTn assays was obtained at presentation from 1098 patients,
of whom 401 (37%) had pre-existing CAD. Patients with pre-
existing CAD differed in several baseline characteristics from
those without pre-existing CAD (Table 1).
Acute myocardial infarction was the adjudicated final diagnosis in
19% of patients with pre-existing CAD when compared with 14%
in patients without pre-existing CAD (P, 0.01). In patients with
pre-existing CAD, other adjudicated diagnoses included UA in
27%, cardiac symptoms from causes other than CAD in 10%, non-
cardiac causes in 34%, and symptoms of unknown origin in 10%
(Table 2).
Cardiac troponin levels at presentation
Among the patients, whose final diagnosis was not an AMI, patients
with pre-existing CAD had significantly higher baseline levels of all
three more sensitive cTn compared with patients without a history
of CAD: median levels in CAD patients were 0.014 mg/dL (IQR:
0.009–0.024), with hs-cTnT; 0.01 mg/dL (IQR: 0.004–0.025),
with cTnI-Ultra; and 0.003 mg/dL (IQR: 0–0.011), with
Abbott-Architect cTnI; compared with 0.005 mg/dL (IQR:
0.003–0.009), with hs-cTnT; 0.004 mg/dL (IQR: 0.001–0.011),
with cTnI-Ultra; and 0.000 mg/dL (IQR: 0.000–0.002),
with Abbott-Architect cTnI in patients without a history of CAD
(P, 0.001 for all comparisons).
Forty per cent of the CAD patients, with a final diagnosis other
than AMI, had elevated baseline levels above the 99th percentile
with the hs-cTnT, 15% had elevated baseline levels above the
99th percentile with the Siemens cTnI-Ultra, and 13% had elevated
baseline levels above the 99th percentile with the
Abbott-Architect cTnI assay. Among patients without a history
of CAD the percentages were significantly smaller (18%, 9 and
7%; P, 0.001, P ¼ 0.002, and P ¼ 0.004, respectively; see
Figure 1). Among all patients with elevated cTn levels above the
99th percentile measured with the hs-cTnT, the Siemens
cTnI-Ultra, and the Abbott-Architect cTnI assay 24%, 10 and 9%,
had UA while 34%, 9 and 7% had non-cardiac chest pain,
respectively (see Table 3).
Diagnostic accuracy of cardiac troponin
in the early diagnosis of acute myocardial
infarction
In patients with pre-existing CAD, the diagnostic accuracy for AMI,
quantified by the AUC, was significantly higher with the sensitive
cTn assays than that with the standard assay (AUC for Roche
hs-cTnT, 0.92; 95% CI: 0.89–0.95; for Siemens cTnI-Ultra, 0.94;
95% CI: 0.91–0.96; and for Abbott-Architect cTnI, 0.93; 95% CI:
0.90–0.95; vs. AUC for the standard assay, 0.87; 95% CI: 0.83–
0.90; P ¼ 0.01, P ¼ 0.003, P ¼ 0.007, respectively, for comparisons;
Table 4, Supplementary material online, Table S4B and Figure 2A).
Overall, the diagnostic accuracy was similar among the three sen-
sitive assays (P . 0.05).
Optimal cut-off for cardiac troponin in
the early diagnosis of acute myocardial
infarction determined by receiver
operating characteristic curve
The optimal cut-off value to separate AMI from non-AMI deter-
mined by ROC analysis in CAD patients was more than twice
the 99th percentile for hs-cTnT [0.030 ng/mL (30 ng/L)], and
close to the 99th percentile for both sensitive cTnI assays
[0.034 ng/mL (34 ng/L) for Abbott-Architect cTnI and 0.046 ng/
mL (46 ng/L) for Siemens cTnI-Ultra; see Table 5 and Figure 2A].
The optimal cut-off value to separate AMI from non-AMI in
patients without a history of CAD was close to the 99th percentile
for hs-cTnT [0.020 ng/mL (20 ng/L)] and half the 99th percentile
for Abbott-Architect cTnI [0.015 ng/mL (15 ng/L); see Table 5
and Figure 2C].
Diagnostic performance in the early
diagnosis of acute myocardial infarction
at the 99th percentile
Overall, at the 99th percentile, all cTn assays showed lower speci-
ficity in patients with pre-existing CAD when compared with
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Table 1 Baseline characteristics of the patients
All patients
(n 5 1098)
Patients with a
history of CADa
(n5 401)
Patients without a
history of CAD
(n 5 697)
P-value* Patients with a history of CAD
Acute myocardial infarction P-value
Yes (n 5 77) No (n 5 324)
Male gender, no (%) 756 (67) 307 (77) 424 (61) ,0.001 58 (75) 249 (77) 0.78
Age, year
Median 64 72 59 ,0.001 75 70 ,0.001
Inter-quartile range 51–75 59–79 47–72 68–84 57–78
Risk factors, no (%)
Hypertension 693 (63) 320 (82) 361 (53) ,0.001 63 (82) 267 (82) 0.90
Hypercholesterolaemia 492 (45) 282 (71) 210 (30) ,0.001 49 (64) 233 (72) 0.15
Diabetes 217 (20) 126 (31) 91 (13) ,0.001 26 (34) 100 (31) 0.59
Current smoking 265 (24) 74 (19) 191 (27) 0.001 18 (23) 56 (17) 0.21
History of smoking 391 (36) 194 (48) 197 (28) ,0.001 31 (40) 163 (50) 0.11
History, no (%)
Previous myocardial
infarction
271 (25) 271 (68) 0 ,0.001 54 (70) 217 (67) 0.60
Previous
revascularization
296 (27) 295 (74) 1 (0)b ,0.001 49 (64) 245 (76) 0.03
Previous PCI 254 (23) 253 (63) 1 (0)b ,0.001 37 (48) 216 (67) 0.002
Previous CABG 111 (10) 111 (28) 0 ,0.001 24 (31) 87 (27) 0.45
Peripheral artery disease 76 (7) 57 (14) 19 (3) ,0.001 15 (20) 42 (13) 0.14
Impaired kidney function 115 (11) 88 (22) 27 (4) ,0.001 23 (30) 65 (20) 0.06
Previous stroke 64 (6) 32 (8) 32 (5) 0.02 11 (14) 21 (7) 0.02
Vital Status, median (IQR)
Heart rate, b.p.m. 75 (66–89) 71 (62–82) 78 (68–92) ,0.001 80 (65–97) 69 (61–79) ,0.001
Systolic blood pressure,
mmHg
142 (127–160) 138 (124–157) 144 (129–161) ,0.001 140 (118–162) 138 (124–155) 0.87
Diastolic blood pressure,
mmHg
84 (74–93) 80 (70–89) 86 (77–95) ,0.001 78 (67–88) 80 (71–89) 0.28
Body mass index 26 (24–30) 27 (24–30) 26 (24–29) 0.062 26 (24–29) 27 (24–30) 0.05
Medication
ACE inhibitors/AT-II
blockers
536 (49) 270 (67) 266 (38) ,0.001 53 (69) 203 (63) 0.33
ASA 420 (38) 297 (74) 123 (18) ,0.001 56 (73) 241 (75) 0.77
Beta-blockers 411 (37) 288 (72) 123 (18) ,0.001 47 (61) 241 (74) 0.02
Calcium antagonists 184 (17) 120 (30) 64 (9) ,0.001 21 (5) 99 (30) 0.57
Diuretics 299 (27) 170 (42) 129 (19) ,0.001 45 (58) 125 (38) 0.002
Lipid-lowering drugs 393 (36) 293 (73) 100 (14) ,0.001 48 (62) 245 (76) 0.02
Nitrates/molsidomin 132 (12) 109 (27) 23 (3) ,0.001 29 (38) 80 (25) 0.02
ECG
Potential ischaemic ECG
changes
247 (23) 109 (27) 138 (20) 0.004 41 (53) 68 (21) ,0.001
ST-segment elevation 58 (5) 19 (5) 39 (6) 0.556 12 (16) 7 (2) ,0.001
ST-segment depression 131 (12) 57 (14) 74 (11) 0.071 29 (38) 28 (8) ,0.001
Abnormal Q-wave 112 (10) 75 (19) 37 (5) ,0.001 14 (18) 61 (19) 0.90
Left bundle branch
block
42 (4) 25 (6) 17 (2) 0.001 13 (17) 12 (4) ,0.001
T-wave inversion 147 (13) 71 (18) 76 (11) 0.001 24 (31) 47 (14) 0.001
aCAD, coronary artery disease.
bPatient with aortal dissection and consecutive coronary dissection but without relevant coronary artery disease.
*x2 test for comparison of proportions of patients with a history of coronary artery disease and patients without coronary artery disease.
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patients without a history of CAD (Table 4). The decrease in speci-
ficity was particularly pronounced with hs-cTnT (59% in CAD
patients vs. 81% in patients without a history of CAD, P, 0.001).
Diagnostic accuracy of cardiac troponin in
the diagnosis of ACS (acute myocardial
infarction or unstable angina)
The diagnostic accuracy for acute coronary syndroms (ACS), quan-
tified by the AUC, was similarly low with the three sensitive cTn
assays in patients with pre-existing CAD, (AUC for Roche
hs-cTnT, 0.66; 95% CI: 0.61–0.70; for Siemens cTnI-Ultra, 0.67;
95% CI: 0.62–0.72; and for Abbott-Architect cTnI, 0.67; 95% CI:
0.63–0.72), but moderate to high in patients without a history of
CAD (AUC for Roche hs-cTnT 0.89; 95% CI: 0.86–0.91; AUC
for Siemens cTnI-Ultra,0.86, 95% CI: 0.83–0.89; AUC for
Abbott-Architect cTnI, 0.86, 95% CI: 0.83–0.88; P, 0.001 for all
comparisons of AUC in patients with vs. without a history of
CAD). For the diagnosis of acute coronary syndromes (AMI or
UA), the negative predictive value of a measured cTn-value
Figure 1 Baseline levels of sensitive troponin assays at presentation. Cardiac troponin levels at presentation displayed as multiples of the 99th
percentile. Boxes represent inter-quartile ranges, while whiskers display ranges (without outliers further than 1.5 inter-quartile ranges). CAD
denotes coronary artery disease. Left side: in patients with final diagnosis of acute myocardial infarction, troponin levels compared within assays
were similar in patients with pre-existing coronary artery disease compared with patients without a history of coronary artery disease (all
P. 0.05). Right side: in patients with final diagnosis other than acute myocardial infarction, troponin levels compared within assays were sig-
nificantly higher in patients with pre-existing coronary artery disease (all P, 0.001).
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Table 2 Final diagnoses of the patients
All patients (n5 1098) History of CADa (n5 401) No history of CAD (n5 697) P-value*
Acute myocardial infarction 173 (16) 77 (19) 96 (14) 0.02
ST-segment elevation 41 (4) 15 (4) 26 (4) 0.99
Non-ST-segment elevation 132 (12) 62 (16) 70 (10) 0.01
UA 152 (14) 108 (27) 44 (6) ,0.001
Cardiac cause, but not CAD 147 (13) 39 (10) 108 (16) 0.01
Non-cardiac cause 528 (48) 136 (34) 392 (56) ,0.001
Unknown 98 (9) 41 (10) 57 (8) 0.25
aCAD, coronary artery disease.
*x2 test for comparison of proportions of patients with a history of coronary artery disease and patients without coronary artery disease.
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below the 99th percentile was 64% (57–71%) for the Roche
hs-cTnT, 65% (60–71%) for the Siemens cTnI-Ultra, and 64%
(58–69%), for the Abbott-Architect cTnI assay. In patients
without a history of CAD, the negative predictive value was 93%
(91–95%), 92% (89–94%), and 91% (88–93%), respectively.
Cardiac troponin levels in patients
with recent onset of chest pain
In patients with pre-existing CAD the superiority of the sensitive
cTn assays in the diagnosis of AMI was most pronounced among
patients with recent onset of chest pain (Figure 2B, Figure 3, and
Supplementary material online, Table S4A).
Among CAD patients who presented within 3 h after the onset
of chest pain (n ¼ 167), the AUCs for the four assays were as
follows: Roche hs-cTnT, 0.86 (95% CI: 0.80–0.91); Siemens
cTnI-Ultra, 0.96 (95% CI: 0.92–0.98); Abbott-Architect cTnI,
0.93 (95% CI: 0.89–0.97); and the standard assay, 0.76 (95% CI:
0.64–0.88) (P, 0.01, P, 0.001, P, 0.001, respectively, for the
comparisons of the sensitive assays with the standard assay). The
AUCs of the sensitive cTnI assays, Siemens cTnI-Ultra and
Abbott-Architect cTnI, were higher than the AUC of the Roche
hs-cTnT assay (P ¼ 0.012 and P ¼ 0.051, respectively; Figure 2B
and Figure 3).
For patients without a history of CAD, who presented within
3 h to the ED, the three sensitive cTn assays had comparable
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Table 4 Diagnostic performance of sensitive troponin assays at the 99th percentile; at 10% coefficient of variation for
the standard assay (95% CI)
History of CAD No history of CAD P-value*
Sensitive troponin assays
Roche high-sensitive troponin T 99th percentile
[0.014 ng/mL (14 ng/L)]
Sensitivity 94 (85–98) 94 (87–98) 0.998
Specificity 59 (54–65) 81 (78–84) ,0.001
Negative predictive value 97 (94–99) 99 (97–100) 0.452
Positive predictive value 35 (29–41) 45 (39–52) 0.137
Siemens troponin I ultra 99th percentile
[0.040 ng/mL (40 ng/L)]
Sensitivity 91 (82–96) 89 (81–94) 0.880
Specificity 85 (80–88) 91 (88–93) 0.007
Negative predictive value 98 (95–99) 98 (97–99) 0.883
Positive predictive value 58 (49–67) 62 (53–69) 0.832
Abbott-Architect troponin I 99th percentile
[0.028 ng/mL (28 ng/L)]
Sensitivity 83 (73–91) 85 (77–92) 0.918
Specificity 87 (83–91) 93 (91–95) 0.016
Negative predictive value 96 (93–98) 98 (96–99) 0.292
Positive predictive value 61 (51–70) 66 (57–74) 0.719
Standard troponin assay
Roche troponin T 4th generation 99th percentile
(unknown) 10% CV (0.035 ng/mL)
Sensitivity 69 (57–79) 83 (57–77) 0.988
Specificity 97 (94–99) 95 (96–99) 0.788
Negative predictive value 93 (90–95) 95 (93–96) 0.417
Positive predictive value 84 (73–92) 83 (73–90) 0.958
CAD, coronary artery disease; CV, coefficient of variation.
*x2 test for comparison of proportions of patients with a history of coronary artery disease and patients without coronary artery disease.
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Table 3 Final diagnoses of patients with cardiac troponin levels above the 99th percentile
High-sensitive troponin T
(n5 402)
Siemens troponin I ultra
(n 5 257)
Abbott-Architect troponin I
(n5 229)
Acute myocardial infarction 162 (40) 155 (60) 146 (64)
ST-segment elevation 125 (31) 119 (46) 114 (50)
Non-ST-segment elevation 37 (9) 36 (14) 32 (14)
UA 58 (14) 26 (10) 21 (9)
Cardiac cause, but not CAD 71 (18) 44 (17) 39 (17)
Non-cardiac cause 81 (20) 23 (9) 16 (7)
Unknown 30 (8) 9 (4) 7 (3)
CAD, coronary artery disease.
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accuracy (AUC for Roche hs-cTnT, 0.93; 95% CI: 0.90–0.96;
Siemens cTnI-Ultra, 0.93; 95% CI: 0.90–0.96; Abbott-
ArchitectcTnI, 0.91; 95% CI: 0.88–0.94; Figure 2D and Figure 3).
Serial cardiac troponin levels
During serial sampling the AUC for all cTn assays increased (Sup-
plementary material online, Table S4B). Absolute values of changes
in high-sensitive cTn levels from presentation to 1 and 2 h alone
had similar diagnostic accuracy as the baseline high-sensitive cTn
levels. The combination of baseline levels plus early changes
improved the performance of the baseline level for all cTn
assays. With the hs-cTnT assay and the Siemens cTnI-Ultra assay
this increase in accuracy was statistically significant for the combi-
nation of the baseline level and the change already within the first
hour after presentation (P ¼ 0.032 and P ¼ 0.039, respectively);
with the Abbott-Architect cTnI assay this increase was only signifi-
cant for the combination of the baseline level and the change
within 2 h after presentation (P ¼ 0.02; Supplementary material
online, Table S4C ).
With the standard assay the diagnostic performance of the com-
bination of baseline levels plus early change at 2 h was superior to
that of the combination of baseline levels and early change at 1 h.
The diagnostic performance of the combinations was higher than
that of early changes alone, and superior to the single measure-
ment at presentation (all P-values, 0.05; see Supplementary
material online, Table S4C ).
Prognostic value of sensitive cardiac
troponin assays
Median follow-up was 379 days (IQR: 107–721) days. Among the
whole cohort, 58 patients died and 53 patients sustained an AMI
during follow-up. Cumulative survival rates for patients with
pre-existing CAD were 0.88 at 1 year vs. 0.98 in patients
without a history of CAD (log-rank test: P, 0.001). In patients
with AMI, survival rates at 1 year were 0.82 vs. 0.97 in patients
with other diagnoses than AMI (log-rank test: P, 0.001). In
patients with elevated levels of Roche hs-cTnT, Siemens
cTnI-Ultra, and Abbott-Architect cTnI above the 99th percentile,
survival rates were 0.87, 0.83, 0.85 vs. 0.99, 0.98, 0.97 in patients
with cTn levels below the 99th percentile (all comparisons by
log-rank test ,0.001; for details see Supplementary material
Figure 2 Diagnostic performance of cardiac troponin at presentation. Receiver operating characteristic curves describing the diagnostic per-
formance of different cardiac troponin assays at presentation for the diagnosis of acute myocardial infarction in patients with a history of cor-
onary artery disease (top), and in those without a history of coronary artery disease (bottom). Left side: presenting within 12 h from chest pain
onset/maximum. Right side: presenting within 3 h. (A) and (C) The calculated optimal cut-off values for patients with and without a history of
coronary artery disease are defined by the point farthest from the point (0,1) of the graph.
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online, Table S5A and B in the Supplementary material online,
Appendix).
Elevated levels of Roche hs-cTnT as well as Siemens
cTnI-Ultra above the 99th percentile strongly predicted mortality
independent of the presence of pre-existing CAD, age, sex,
arterial hypertension, and diabetes in all patients (HR: 2.3, 95%
CI: 1.1–5.1, P ¼ 0.034; HR: 2.3, 95% CI: 1.2–4.4, P ¼ 0.009;
respectively).
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Table 5 Diagnostic performance of sensitive troponin assays in patients with pre-existing coronary artery disease at the
optimal cut-off determined by the receiver operating characteristic curve (95% CI)
Optimal cut-off
ROC
Corresponding
cTn valuesa
Optimal
cut-off
ROC
99th
percentile
P-value*
Sensitive troponin assays
Patients with pre-existing coronary artery disease
Roche high-sensitive troponin T 99th percentile
[0.014 ng/mL (14 ng/L)]
0.030 ng/mL (30 ng/L) 0.025–0.035 Sensitivity 83 (73–91) 94 (85–98) 0.008
Specificity 86 (82–89) 60 (54–65) ,0.001
Siemens troponin I ultra 99th percentile
[0.040 ng/mL (40 ng/L)]
0.046 ng/mL (46 ng/L) 0.034–0.083 Sensitivity 88 (79–95) 91 (82–96) 0.500
Specificity 89 (85–92) 85 (80–88) ,0.001
Abbott-Architect troponin I 99th percentile
[0.028 ng/mL (28 ng/L)]
0.034 ng/mL (34 ng/L) 0.020–0.061 Sensitivity 83 (73–91) 83 (73–91) 1
Specificity 90 (86–93) 87 (83–91) 0.008
Sensitive troponin assays
Patients without pre-existing coronary artery disease
Roche high-sensitive troponin T 99th percentile
[0.014 ng/mL (14 ng/L)]
0.020 ng/mL (20 ng/L) 0.016–0.025 Sensitivity 91 (83–96) 94 (87–98) 0.250
Specificity 88 (86–91) 82 (79–85) ,0.001
Siemens troponin I ultra 99th percentile
[0.040 ng/mL (40 ng/L)]
0.045 ng/mL (45 ng/L) 0.029–0.066 Sensitivity 89 (80–94) 89 (80–94) 1
Specificity 93 (90–95) 91 (89–93) 0.016
Abbott-Architect troponin I 99th percentile
[0.028 ng/mL (28 ng/L)]
0.015 ng/mL (15 ng/L) 0.010–0.024 Sensitivity 90 (82–95) 85 (77–92) 0.125
Specificity 90 (87–92) 93 (91–95) ,0.001
*Comparisons among patients by McNemar x2 test.
acTn values that correspond to the 95% confidence interval of the sensitivity at the ROC-derived optimal cut-off.
Figure 3 Diagnostic accuracy at presentation according to chest pain onset. Area under the receiver operating characteristic curves and 95%
confidence intervals for the different cardiac troponin assays at presentation in the diagnosis of acute myocardial infarction according to the
time from the onset of chest pain. Left: patients with a history of coronary artery disease. Right: patients without a history of coronary
artery disease.
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In Cox regression analyses, adjusting for pre-existing CAD, age,
sex, arterial hypertension, and hypercholesterolaemia, none of the
sensitive cTn assays predicted AMI during follow-up (all P-values
not significant).
Discussion
In this prospective multicentre study, we address important issues
related to the clinical application of sensitive cTn assays and exam-
ined the impact of pre-existing CAD on their diagnostic and prog-
nostic accuracy. We provide seven important findings with impact
on their best possible use in the early diagnosis of AMI:.
First, the prevalence of elevated sensitive cTnI and hs-cTnT
levels above the 99th percentile in CAD patients with a final diag-
nosis other than AMI was high and differed largely among the three
novel cTn assays, ranging from 13 to 40%. Clinically, the high inci-
dence of elevated cTn levels in CAD patients challenges the appli-
cation of the 99th percentile for the decision limit for the diagnosis
of AMI, as suggested in current guidelines. Careful clinical assess-
ment and thoughtful differential diagnosis are required to separate
AMI from a variety of acute and chronic disorders also associated
with low-level myocardial necrosis.24 In addition, the difference
regarding the incidence of cTn levels above the 99th percentile
in CAD patients without AMI might indicate the presence of
important differences in the release of cTnI and cTnT in these
non-AMI settings, which is further supported by recent data.11,12
An alternative explanation for the difference regarding the inci-
dence of elevated cTn levels is the fact that the 99th percentiles
for the three sensitive assays were not determined in the same
reference population.
Second, for all three sensitive cTn assays, the diagnostic accuracy
at presentation was nevertheless significantly higher than with the
standard assay in CAD patients as well as in patients without a
history of CAD.
Third, the ROC-derived optimal cut-off levels for CAD patients
tended to be higher than in patients without a history of CAD,
although the AUC of sensitive cTn assays did not differ significantly
comparing CAD and non-CAD patients. All cTn assays showed
higher sensitivity but lower specificity in CAD patients when com-
pared with patients without a history of CAD, reflecting the higher
baseline levels in CAD patients without AMI. These findings high-
light the clinical need to develop test-specific algorithms that fine
tune the application of these novel tests in patients with acute
chest pain.12
Fourthly, the superiority of the sensitive cTn assays was most
pronounced among CAD patients with a recent onset of chest
pain, offering the opportunity to minimize myocardial damage by
extending early treatment options to AMI patients without
ST-segment elevation.1,2
Fifthly, the sensitive cTnI assays seemed to outperform the
hs-cTnT assay in early presenters.
Sixthly, the accuracy of sensitive cTn assays to diagnose ACS
(AMI or UA) was significantly lower in patients with pre-existing
CAD when compared with patients without pre-existing CAD.
Further research is necessary to identify biomarkers that reliably
detect myocardial ischaemia irrespective of necrosis, particularly
in patients with pre-existing CAD.25
Seventhly, the Roche hs-cTnT and the sensitive Siemens
cTnI-Ultra assay predict mortality independent of age, sex, pre-
existing CAD, and cardiovascular risk factors. Our findings
extend the results of previous studies, investigating the mortality
of apparently healthy subjects with elevated levels measured
with sensitive cTnI assays.11,26,27
The following limitations of the current study merit consider-
ation. First, we evaluated three sensitive cTn assays. We hypoth-
esize that our findings can be generalized to other cTn assays
with similar sensitivity and precision. However, additional studies
need to confirm this hypothesis. Secondly, in this ongoing prospec-
tive study, the subgroup analysis of patients with pre-existing CAD
was not predefined at the time of the initial protocol written in
2005. It was added while we were still blinded to the results in
2009, with regard to recent investigations, challenging the diagnos-
tic accuracy of sensitive cTn assays in CAD patients.11,12 Therefore,
e.g. our analysis of the assay-specific ROC-derived optimal cut-off
values to differentiate AMI from other causes of acute chest pain
should be considered exploratory and requires confirmation in
additional studies. Third, this observational study cannot quantify
exactly the clinical benefit associated with the increase in early
diagnostic accuracy. To add this important information, interven-
tion studies seem warranted. Fourth, the first 800 blood samples
for the hs-cTnT assay were collected into tubes containing
serum, while all other blood samples were collected into tubes
containing potassium EDTA, which might lead to slightly different
concentration values. Fifthly, some of the patients with positive
sensitive cTn values classified as non-AMIs might have had small
AMIs below the decision value of conventional cTn. Presumably,
this contributed to the reduced specificity of the sensitive assays.
In conclusion, sensitive cTn assays introduce diagnostic improve-
ments as well as challenges. The excellent diagnostic performance
of sensitive cTn assays in the early diagnosis of AMI can be
extended to patients with pre-existing CAD. However, elevated
cTn levels at presentation are common also in CAD patients
with diagnoses other than AMI, challenging differential diagnosis.
Accordingly, the accuracy to diagnose ACS was lower in patients
with pre-existing CAD when compared with patients without pre-
existing CAD and optimal cut-off levels tend to be higher. Sensitive
cTn assays have prognostic value in patients with a final diagnosis
other than AMI.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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